The peroxisome proliferator–activated receptor-γ (PPAR-γ) agonist rosiglitazone, originally used as an antidiabetic drug functioning as an insulin sensitizer, has shown to increase levels of Ang1 while lowering the Ang2:Ang1 ratio in malaria, and has thus been tested in clinical trials in pediatric patients with malaria [92,93]. The gene discussed is PPARG; the disease is malaria.